脾脏专用硬度测量在排除HBV相关肝细胞癌高危静脉曲张中表现良好:肝细胞癌高危静脉曲张筛查
这项前瞻性研究纳入219例HBV相关代偿期肝硬化新诊断肝细胞癌患者,评估Baveno VI、Baveno VII算法及100 Hz脾脏硬度测量(SSM≤40 kPa)排除高危静脉曲张(HRV)的能力。HRV患病率28.8%,SSM≤40 kPa安全避免47.5%内镜检查(HRV漏诊率4.8%),优于Baveno VI(p<0.001),与Baveno VII相当(p=0.390);Baveno VII在肝细胞癌患者中的效力需进一步研究。
要点
- SSM≤40 kPa安全避免47.5%内镜检查,HRV漏诊率4.8%,优于Baveno VI(p<0.001)。
- Baveno VI避免27.4%内镜检查(HRV漏诊率3.2%),Baveno VII避免49.3%(漏诊率7.9%)。
- SSM≤40 kPa在米兰标准内、合并门静脉癌栓或BCLC B/C或全身治疗候选者中均安全避免内镜。
核心结论
- 100 Hz探头SSM≤40 kPa在HBV相关肝细胞癌患者中比Baveno VI安全排除更多不必要内镜检查;Baveno VII算法在肝细胞癌患者中的效力需进一步研究。
研究设计与样本
- 前瞻性纳入连续HBV相关代偿期肝硬化新诊断肝细胞癌患者,行肝脏硬度测量、100 Hz剪切波频率脾脏硬度测量(SSM)及食管胃十二指肠镜(EGD)检查。
- 2021年9月至2023年8月共纳入219例肝细胞癌患者,BCLC A期107例(48.9%)、B期28例(12.8%)、C期84例(38.3%)。
主要发现
- 高危静脉曲张(HRV)患病率为28.8%(63/219)。
- Baveno VI标准安全(HRV漏诊率3.2%)避免27.4%不必要EGD;Baveno VII算法避免49.3%,HRV漏诊率7.9%(5/63)。
- SSM≤40 kPa安全避免47.5%的EGD(HRV漏诊率4.8%),显著优于Baveno VI标准(p<0.001),与Baveno VII算法相当(p=0.390)。
- SSM≤40 kPa在米兰标准内、合并门静脉癌栓、BCLC B/C或全身治疗候选者亚组中均安全避免EGD。
关键数值与推荐
- Baveno VI标准:HRV漏诊率3.2%,避免27.4%不必要EGD。
- Baveno VII算法:HRV漏诊率7.9%(5/63),避免49.3%不必要EGD。
- SSM≤40 kPa(100 Hz探头):HRV漏诊率4.8%,避免47.5%不必要EGD;与Baveno VI比较p<0.001,与Baveno VII比较p=0.390。
临床怎么用
- 在HBV相关代偿期肝硬化新诊断肝细胞癌患者中,采用100 Hz探头SSM≤40 kPa可安全排除高危静脉曲张,减少不必要EGD。
- SSM≤40 kPa在米兰标准内、合并门静脉癌栓、BCLC B/C或全身治疗候选者亚组中同样可安全避免EGD。
- Baveno VII算法在肝细胞癌患者中的效力需进一步研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Esophagogastroduodenoscopy (EGD) is required to screen for high-risk varices (HRV) in patients with hepatocellular carcinoma (HCC), especially since overall survival rates have dramatically improved with new systemic therapies. AIM: To assess the Baveno VI and Baveno VII algorithms' ability to rule out HRV in hepatitis B virus (HBV)-related HCC METHODS: We prospectively enrolled consecutive patients with HBV related, compensated cirrhosis and newly diagnosed HCC who underwent liver stiffness measurement, spleen stiffness measurement (SSM) using a 100-Hz shear wave frequency, and EGD. RESULTS: From September 2021 to August 2023, we enrolled 219 patients with HCC, with 107 (48.9%) Barcelona Clinic Liver Cancer (BCLC) A, 28 (12.8%) BCLC B and 84 (38.3%) BCLC C, respectively. HRV prevalence was 28.8% (63/219). Baveno VI criteria safely (HRV missing rate, 3.2%) avoided 27.4% unnecessary EGDs, while the Baveno VII algorithm avoided 49.3% with HRV missing rate at 7.9% (5/63). The SSM ≤40 kPa avoided 47.5% of EGDs safely (HRV missing rate, 4.8%), significantly better than the Baveno VI criteria (p < 0.001) and comparable to the Baveno VII algorithm (p = 0.390). The SSM ≤40 kPa safely avoided EGDs in patient subgroups within Milan criteria, with portal vein tumour thrombosis or BCLC B/C or candidates for systemic therapy. CONCLUSIONS: We validated that the SSM ≤40 kPa using a 100-Hz probe could safely eliminate more unnecessary EGDs than the Baveno VI criteria in patients with HBV-related HCC. However, the efficacy of the Baveno VII algorithm in patients with HCC requires further investigation.
引用
- Cheng X, Tang Y, He Q, et al. Spleen-dedicated stiffness measurement performed well to rule out high-risk varices in HBV-related hepatocellular carcinoma: Screening for high-risk varices in HCC. Aliment Pharmacol Ther. 2023. PMID: 38155565. doi:10.1111/apt.17850
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。